{"nctId":"NCT01356498","briefTitle":"Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout","startDateStruct":{"date":"2006-12"},"conditions":["Gout"],"count":151,"armGroups":[{"label":"q2 RCT","type":"EXPERIMENTAL","interventionNames":["Biological: pegloticase"]},{"label":"q4 RCT","type":"EXPERIMENTAL","interventionNames":["Biological: pegloticase"]},{"label":"Placebo in RCT","type":"EXPERIMENTAL","interventionNames":["Biological: pegloticase"]}],"interventions":[{"name":"pegloticase","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed treatment in one of two double-blind, placebo controlled studies of PEG-uricase in subjects with hyperuricemia and symptomatic gout\n\nExclusion Criteria:\n\n* unstable angina\n* uncontrolled arrhythmia\n* uncontrolled hypertension\n* end stage renal disease requiring dialysis\n* anemia","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Uric Acid (mg/dL)","description":"Uric acid measured at 3 month-intervals","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"3.103"},{"groupId":"OG001","value":"1.91","spread":"4.082"},{"groupId":"OG002","value":"5.06","spread":"4.538"},{"groupId":"OG003","value":"9.76","spread":"1.346"},{"groupId":"OG004","value":"9.66","spread":"2.529"},{"groupId":"OG005","value":"8.08","spread":"3.561"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"3.196"},{"groupId":"OG001","value":"1.95","spread":"3.761"},{"groupId":"OG002","value":"4.69","spread":"4.454"},{"groupId":"OG003","value":"8.89","spread":"3.984"},{"groupId":"OG004","value":"9.94","spread":"2.646"},{"groupId":"OG005","value":"8.09","spread":"3.536"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":"2.327"},{"groupId":"OG001","value":"1.55","spread":"3.690"},{"groupId":"OG002","value":"2.7","spread":"4.255"},{"groupId":"OG003","value":"9.18","spread":"2.946"},{"groupId":"OG004","value":"9.59","spread":"2.782"},{"groupId":"OG005","value":"6.45","spread":"3.248"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"2.619"},{"groupId":"OG001","value":"1.47","spread":"3.317"},{"groupId":"OG002","value":"4.29","spread":"3.985"},{"groupId":"OG003","value":"7.7","spread":"4.244"},{"groupId":"OG004","value":"9.42","spread":"1.961"},{"groupId":"OG005","value":"8.5","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Tophus Response","description":"Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcome: SF-36 Physical Component Summary Score","description":"SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best).\n\nThe Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.92","spread":"10.988"},{"groupId":"OG001","value":"34.11","spread":"10.022"},{"groupId":"OG002","value":"27.55","spread":"11.405"},{"groupId":"OG003","value":"33.71","spread":"11.581"},{"groupId":"OG004","value":"32.8","spread":"10.129"},{"groupId":"OG005","value":"36.2","spread":"11.926"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.40","spread":"13.393"},{"groupId":"OG001","value":"40.82","spread":"7.482"},{"groupId":"OG002","value":"30.34","spread":"11.132"},{"groupId":"OG003","value":"37.68","spread":"10.298"},{"groupId":"OG004","value":"34.76","spread":"11.413"},{"groupId":"OG005","value":"38.8","spread":"13.155"}]}]}]},{"type":"SECONDARY","title":"Gout Flare Frequency","description":"The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.69"},{"groupId":"OG001","value":"0.8","spread":"0.90"},{"groupId":"OG002","value":"2.3","spread":"2.91"},{"groupId":"OG003","value":"0.6","spread":"0.90"},{"groupId":"OG004","value":"1.3","spread":"1.49"},{"groupId":"OG005","value":"1.5","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.96"},{"groupId":"OG001","value":"0.7","spread":"0.95"},{"groupId":"OG002","value":"1.3","spread":"2.17"},{"groupId":"OG003","value":"1.0","spread":"1.73"},{"groupId":"OG004","value":"0.8","spread":"0.94"},{"groupId":"OG005","value":"0.8","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.17"},{"groupId":"OG001","value":"0.3","spread":"0.54"},{"groupId":"OG002","value":"1.2","spread":"1.80"},{"groupId":"OG003","value":"0.6","spread":"1.20"},{"groupId":"OG004","value":"0.6","spread":"0.97"},{"groupId":"OG005","value":"0.4","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.30"},{"groupId":"OG001","value":"0.2","spread":"0.51"},{"groupId":"OG002","value":"0.6","spread":"1.18"},{"groupId":"OG003","value":"0.9","spread":"1.34"},{"groupId":"OG004","value":"0.9","spread":"1.46"},{"groupId":"OG005","value":"0.4","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.25"},{"groupId":"OG001","value":".3","spread":"0.44"},{"groupId":"OG002","value":"0.2","spread":"0.40"},{"groupId":"OG003","value":"0.7","spread":"1.18"},{"groupId":"OG004","value":"0.6","spread":"0.85"},{"groupId":"OG005","value":"0.4","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.37"},{"groupId":"OG001","value":"0.1","spread":"0.23"},{"groupId":"OG002","value":"0.4","spread":"0.67"},{"groupId":"OG003","value":"0.3","spread":"0.65"},{"groupId":"OG004","value":"0.6","spread":"0.53"},{"groupId":"OG005","value":"0.7","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Gout Flare Incidence","description":"Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"65.2","spread":null},{"groupId":"OG003","value":"45.5","spread":null},{"groupId":"OG004","value":"67.9","spread":null},{"groupId":"OG005","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"45.0","spread":null},{"groupId":"OG003","value":"35.0","spread":null},{"groupId":"OG004","value":"50.0","spread":null},{"groupId":"OG005","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"24.0","spread":null},{"groupId":"OG002","value":"43.8","spread":null},{"groupId":"OG003","value":"27.8","spread":null},{"groupId":"OG004","value":"42.9","spread":null},{"groupId":"OG005","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"28.6","spread":null},{"groupId":"OG003","value":"47.1","spread":null},{"groupId":"OG004","value":"45.0","spread":null},{"groupId":"OG005","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"25.0","spread":null},{"groupId":"OG002","value":"18.2","spread":null},{"groupId":"OG003","value":"33.3","spread":null},{"groupId":"OG004","value":"38.9","spread":null},{"groupId":"OG005","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"27.3","spread":null},{"groupId":"OG003","value":"25.0","spread":null},{"groupId":"OG004","value":"55.6","spread":null},{"groupId":"OG005","value":"33.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":35},"commonTop":["Gout","Infusion Related Reaction","Arthralgia","Upper Respiratory Tract Invection","Pain in Extremity"]}}}